Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to the JMJD3 siRNA guide strand represent a class of unintended molecular interactions occurring during RNA interference (RNAi) experiments or therapies. JMJD3, also known as KDM6B, is a histone H3K27 demethylase that plays a critical role in regulating gene expression during inflammation, development, and oncogenesis (Agger et al., 2007, Nature). When siRNAs are designed to silence JMJD3, the guide strand may bind to other mRNA transcripts that share sequence homology, particularly in the 3' untranslated region (UTR) matching the siRNA's seed sequence (Jackson et al., 2003, Nature Biotechnology). This binding leads to the degradation or translational repression of these non-target mRNAs, potentially causing phenotypic changes unrelated to JMJD3 inhibition. These off-target effects are a major hurdle in drug development, as they can lead to toxicity or false-positive results in functional genomics screens (Birmingham et al., 2006, Nature Methods). To minimize these risks, researchers employ chemical modifications, such as 2'-O-methyl groups, or use multiple siRNA sequences to validate findings (Fedorov et al., 2006, RNA). Understanding and predicting these off-target interactions is essential for the clinical translation of siRNA-based drugs targeting JMJD3.
Sequence-specific mRNA degradation or translational repression via the RNA-induced silencing complex (RISC) triggered by partial complementarity, particularly within the seed region (nucleotides 2-8), to the 3' untranslated regions of unintended transcripts (Jackson et al., 2003, Nature Biotechnology).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to JMJD3 siRNA guide strand.